Anticandidal Agents

Langue : Anglais

Auteur : Kumar Awanish

Couverture de l’ouvrage Anticandidal Agents

Résumé
Sommaire
Lectorat
Biographie
Commentaire

Anticandidal Agents provides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules.

Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines.

Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics.

Chapter 1. Introduction

Chapter 2. Host–Pathogen Interaction

Chapter 3. Antifungals Used Against Candidiasis

Chapter 4. Drug Resistance in Candida

Chapter 5. Multidrug Resistance and Transporters

Chapter 6. Potential Anticandidal Targets

Chapter 7. Drug Development Strategies

Chapter 8. Conclusion

Researchers in applied microbiology, molecular biology, mycology, biotechnology, and biochemistry

Dr. Awanish Kumar is currently an Associate Professor in the Department of Biotechnology at the National Institute of Technology, Raipur (CG), India. He is working in the area of infection biology, drug targeting, and drug discovery. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute-Lucknow, India and Jawaharlal Nehru University-Delhi, India. He did his post-doctoral study at McGill University, Montreal, Canada. Dr. Kumar has served various national and international organizations in different academic and research capacities. He has authored several monographs, books, and book chapters. He has served on many national committees, scientific society and advisory panels, is a member of many international professional research societies and as a reviewer and editorial board member of reputed and refereed journals.

Presents a complete understanding of candida resistance to help in the development of therapeutic expansion and novel drugs
Provides thorough information on candida drug resistance and its remedial implications
Covers crucial mechanisms of resistance that will help develop strategies for overcoming the hindrance in current therapeutics